key: cord-0696807-q9n5ogkr
authors: Ríos-Barnés, María; Lanaspa, Miguel; Noguera-Julian, Antoni; Baleta, Laia; Sevilla, Mariona Fernández De; Ferri, David; Götzens, Julià; Jordan, Iolanda; Lecina, Laura; Monfort, Laura; Trabazo, María; Velasco-Arnaiz, Eneritz; Badell, Isabel; Fortuny, Clàudia; Fumadó, Victòria
title: The spectrum of COVID-19 disease in adolescents
date: 2020-09-19
journal: Arch Bronconeumol
DOI: 10.1016/j.arbres.2020.08.016
sha: 43d2e3ddf42889e8fe3dbf0a2d0fe473f924abce
doc_id: 696807
cord_uid: q9n5ogkr

nan

infection and 28,388 (11.3%) deaths attributed to SARS-CoV-2 disease (COVID-19) have been recorded in Spain. 1 However, as of May 8 2020, only 2,158 cases and 7 (0.3%) deaths among Spanish patients aged less than 19 years of age had been reported. 2 The largest series to date agree that most children and adolescents infected with SARS-CoV-2 show a milder clinical course than adults, with severe COVID-19 cases occurring almost exclusively in patients with underlying conditions. 3, 4 Recently, a pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 infection mimicking Kawasaki disease has been described in Europe and the United States. [5] [6] [7] [8] [9] The former does not usually include major respiratory involvement despite cases of severely ill children and adolescents have been reported. A specific analysis of the spectrum of COVID-19 respiratory disease in adolescents is lacking. We aimed to describe COVID-19 pneumonia prevalence and clinical characteristics in a pediatric referall center during the pandemics in Spain. Our case series describes the spectrum of COVID-19 disease in adolescents, and reports almost a 10% prevalence rate of pneumonia in this age range. In a recent study including 48 SARS-CoV-2-infected children and adolescents admitted to the pediatric intensive care unit in the United States and Canada, most patients (73%) presented with respiratory symptoms, 83% had comorbidities and 56% were adolescents. 10 One patient in our series died, he was an 11-yearold boy with relapsing leukeumia and several severe allogenic bone marrow transplantassociated complications. In the American case series, the two fatalities that were reported also occurred in adolescents (aged 12 and 17 years) with significant previous comorbidities. 10 In the lack of evidence-based therapies for the management of COVID-19 at the time of admission, all patients in our series were treated according to local protocols that were adapted from national recommendations. 11 They all received oral azythromycin, oral hydroxycloroquine and intravenous ceftriaxone. In spite of the latter, two patients in our series developed acute respiratory distress syndrome and were also treated with steroids and tocilizumab. A clinical trial has recently demonstrated that dexamethasone reduces 28-day mortality among COVID-19 patients that require respiratory support. 12 The role of tocilizumab, an interleukin-6 receptor inhibitor, and other immunomodulatory agents in the attenuation of COVID-19-related cytokine release syndrome remains to be determined. In our center, positive previous experiences with tocilizumab in the treatment of cytokine release syndrome in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia receiving the anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel prompted its early use in COVID-19 patients. 13 Despite the referral bias and the likely underdiagnosis among asymptomatic or mildly symptomatic SARS-CoV-2-infected adolescents in Spain, our results suggest that COVID-19 more 7 often presents with moderate to severe forms in adolescents than in younger children. Actually, 3 patients in our series had no previous comorbidities and they all presented with hypoxemic pneumonia and hyperinflammation syndromes similar to those described in adults. 14 Nevertheless, our data confirm that the clinical course of COVID-19 pneumonia in adolescents is less severe and outcomes are better than in the adult population.

Interestingly, elevated inflammatory markers at admission (including C-reactive protein, Ddimer and ferritin) correlated with subrogate markers of severity such as duration of admission or duration of respiratory support. Bhumbra et al recently reported similar results: in their casestudy, lower leukocyte and platelet counts and higher C-reactive protein levels at admission were associated with admission in the pediatric intensive care unit. 15 While these results are preliminary and should be confirmed in larger prospective studies, some of these parameters may prove useful in the early identification of adolescents at high risk of severe COVID-19 forms. 

Situación de COVID-19 en España a 6 de Julio de 2020

Situación de COVID-19 en España a 8 de Mayo de 2020

SARS-CoV-2 Infection in children

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID19): a multicentre cohort

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARSCoV-2. JAMA 2020 [Epub ahead of print

Multisystem Inflammatory Syndrome in Children in New York State

Characteristics and Outcomes of Children With Coronavirus Disease

Recomendaciones de tratamiento específico en caso de infección respiratoria por SARS-CoV-2 en pacientes pediátricos con enfermedades crónicas de alto riesgo y en pacientes hospitalizados. Asociación Española de Pediatría

Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv 2020 [Epub ahead of print: 22

Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Clinical Features of Critical Coronavirus Disease 2019 in Children